baicalin has been researched along with entecavir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Huang, H; Shi, X; Zhou, P; Zhou, W; Zhu, H | 1 |
2 other study(ies) available for baicalin and entecavir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs.
Topics: Animals; Animals, Newborn; Antiviral Agents; Biomarkers; Disease Models, Animal; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Ducks; Flavonoids; Guanine; Hep G2 Cells; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 4; Host-Pathogen Interactions; Humans; RNA, Viral; Time Factors; Transcription, Genetic; Transfection; Viral Load | 2017 |